A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.

Trial Profile

A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Masitinib (Primary) ; Etoposide; Irinotecan
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 21 Sep 2017 This trial has been suspended in Slovakia.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jul 2015 In July 2015, an interim analysis was conducted by the DSMB; it was recommended that the study continue as planned, according to an AB Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top